solid revenu ep part
product revenu includ neulasta enbrel in-lin slightli
expect much lower
total rev vs con ep vs con
beat partial due better product sale lower expens half due
beat rev ibranc royalti etc guidanc rais ep
beat pass base math due higher royalti
lack sensipar gener possibl minim impact neulasta biosimilar versu origin
guidanc includ impact biosimilar
notabl thing slide aimovig cgrp note remark respons
doc patient patient start sinc launch grow parabol
 grown quarter compani note expect script activ
moder normal come week due bolu headach bolu center
neulasta estimate q/q price declin contract on-going compani note
competit landscap chang recent biosimilar approv possibl second one
bite cancer drug confirm
phase ii data sensipar risk gener launch yet patent litig
conf call today et dial detail
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
global biotechnolog compani focus develop manufactur commerci novel biotherapeut
primarili cancer nephrolog inflammatori diseas cardiovascular diseas bone diseas pioneer use recombin
dna produc world success blockbust biotech drug compani core busi erythropoietin epo
stimul agent esa epogen aranesp neutrophil stimul franchis neulasta obtain
princip inflammatori diseas busi enbrel acquisit immunex go forward compani primari futur growth
driver repatha antibodi target hyperlipidemia
pt base probability-bas dcf risk includ ip litig biosimilar price competit
michael yee certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
andrew tsai certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
kelechi chiker ph certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
arshad haider certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
case jefferi employe analyst respons coverag financi instrument discuss report receiv
compens base part overal perform firm includ invest bank incom seek updat research
appropri variou regul may prevent us asid certain industri report publish period basi larg major
report publish irregular interv appropri analyst judgement
articl articl
jefferi group llc make market secur adr inc
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within period
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate secur averag
secur price consist expect total return price appreci plu yield plu minu within period
under-perform rate secur averag secur price consist expect total return price appreci plu yield minu
less within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/
jefferi polici
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic secur regul
prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project opinion
invest merit compani provid
page
pleas see import disclosur inform page report
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil expect total
return next month price target base sever methodolog may includ restrict analys market
premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
jefferi franchis pick includ stock select among best stock idea equiti analyst month period stock select
base fundament analysi may take account factor analyst convict differenti analysi favor risk/reward
ratio invest theme jefferi analyst recommend jefferi franchis pick includ buy rate stock number
vari depend analyst recommend inclus stock ad new opportun aris remov reason
inclus chang stock met desir return longer rate buy and/or trigger stop loss stock day volatil
bottom quartil stock continu stop loss remaind stop franchis pick intend
repres recommend portfolio stock sector base may note believ pick fall within invest style
growth valu
risk may imped achiev price target
report prepar gener circul provid invest recommend specif individu investor financi
instrument discuss report may suitabl investor investor must make invest decis base upon
specif invest object financi situat util financi advisor deem necessari past perform financi
instrument recommend report taken indic guarante futur result price valu incom
financi instrument mention report rise well fall may affect chang econom financi polit
factor financi instrument denomin currenc investor home currenc chang exchang rate may advers affect
price valu incom deriv financi instrument describ report addit investor secur adr whose
valu affect currenc underli secur effect assum currenc risk
note box rate price target histori chart repres action past three year analyst initi
compani made chang rate price target compani discontinu coverag compani
import disclosur inform compani recommend report pleas visit websit http //javatar bluematrix com/sellside/
